Category: GlaxoSmithKline plcSyndicate content

Boston Scientific, Covidien get in on SetPoint Medical's $27M round

August 8, 2013 by Brad Perriello

SetPoint Medical raises $27 million, including contributions from Boston Scientific, Covidien and GlaxoSmithKline's new venture investing arm.

Boston Scientific, Covidien get in on SetPoint Medical's $27M round

SetPoint Medical said Boston Scientific (NYSE:BSX) and Covidien (NYSE:COV) were among the participants in a $27 million funding round.

Theravance/Glaxo's Breo Ellipta wins FDA go-ahead

May 15, 2013 by Ingrid Mezo

A drug/device combination for the treatment of chronic obstructive pulmonary disease co-developed by Theravance and GlaxoSmithKline wins FDA approval.

Theravance/Glaxo's Breo Ellipta wins FDA go-ahead

Diabetes: GI Dynamics inks research deals with Medtronic, GlaxoSmithKline

January 9, 2013 by MassDevice staff

GI Dynamics lands research partnerships with Medtronic and GlaxoSmithKline, evaluating the relationship between EndoBarrier intestinal liner treatment and patient glucose levels and hormonal changes.

GI Dynamics logo

Murdock Institute's president steps down; successor expected this summer

June 11, 2011 by MedCity News

The Murdock Research Institute announces that president Micheal Luther has stepped down.

David H. Murdock Research Institute

The David H. Murdock Research Institute expects to name a new leader this summer to succeed president Michael Luther, who has stepped down.

Wright Medical CEO and CTO out

April 5, 2011 by MassDevice staff

A surprise shakeup at orthopedic device maker Wright Medical Group sees CEO Gary Henley abruptly resign and CTO Frank Bono given his walking papers, with analysts speculating the re-shuffle is due to a U.S. Justice Dept. case that cost the company $8 million last year.

WMGI logo

Wright Medical Group Inc. (NSDQ:WMGI) announced a surprise shakeup of its executive team today, firing its chief technology officer and accepting the resignation of CEO Gary Henley.

The Arlington, Tenn.-based maker of orthopedic devices for the foot and ankle market said in a regulatory filing that Henley resigned prior to a board meeting yesterday.

Insulet inks Canadian deal with GlaxoSmithKline | Distribution roundup

March 2, 2011 by MassDevice staff

Bedford, Mass.-based Insulet Corp. signs a distribution deal with GlaxoSmithKline plc for the OmniPod insulin system in Canada.

Distribution Deals Roundup

Insulet Corp. (NSDQ:PODD) inked a Canadian distribution deal with GlaxoSmithKline plc (NYSE:GSK) for its OmniPod insulin management system.

The deal gives the British pharma giant — stung by recent problems with its Avandia diabetes drug — exclusive rights to market and sell Bedford, Mass.-based Insulet's OmniPod system north of the border.